Failure mode and bimodal restenosis of drug-coated balloon in femoropopliteal intervention

被引:7
|
作者
Huang, Hsuan-Li [1 ,2 ]
Chou, Hsin-Hua [1 ,2 ]
Chen, I-Chih [3 ]
Hsieh, Chien-An [1 ]
Jang, Shih-Jung [1 ]
Tzeng, I-Shiang [4 ]
Ko, Yu-Lin [1 ,2 ]
机构
[1] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Div Cardiol, Dept Internal Med, New Taipei, Taiwan
[2] Tzu Chi Univ, Sch Med, Hualien, Taiwan
[3] Tainan Municipal Hosp, Div Cardiol, Dept Internal Med, Tainan, Taiwan
[4] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Res, New Taipei, Taiwan
关键词
Drug-coated balloon; Restenosis; Femoropopliteal; Failure mode; PACLITAXEL-ELUTING STENTS; CLINICAL-OUTCOMES; ARTERY-DISEASE; ZILVER PTX; FEMORAL-ARTERY; CLASSIFICATION; EPIDEMIOLOGY; PREVALENCE; PATTERNS; IMPACT;
D O I
10.1016/j.ijcard.2018.02.040
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pattern of DCB restenosis and associated outcomes in facing complex femoropopliteal lesions remain uncertain. Methods: Data were retrospectively collected from dual centers in Taiwan on patients who underwent treatment with DCBs for femoropopliteal lesions between 2013 and 2016. The restenosis pattern was categorized by the index-treated length. Clinical outcomes and time to DCB restenosis were retrospectively analyzed. Cox proportional hazards model identified restenosis predictors. Results: We recruited a total of 164 patients (91 men; median age 73 years) into the final analysis. The mean lesion length was 204.0 +/- 109.2 mm. Of them, 45% total occlusions, 28% severe calcification and 15% in-stent restenosis were treated. Fifty-five patients have DCB restenosis (28 focal and 27 diffuse-occlusive patterns) over a 55-month follow-up. The median restenosis time emerged as a bimodal pattern with a significant difference between the diffuse-occlusive and focal restenosis group (225 vs. 484 days, P = 0.01). The 1-year patency rate after reintervention for DCB restenosis also was different between both restenosis group (29% vs. 65%, P = 0.017). The anticipated timing of escape for diffuse-occlusive or focal restenosis was 687 and 1068 days, respectively. Independent factorswere lesion length (P = 0.049) for diffuse-occlusive restenosis and lumen gain of the popliteal artery for focal restenosis (P = 0.034). Conclusions: This study demonstrated time to DCB failure emerged as a bimodal pattern of distribution and associations of restenosis pattern to subsequent outcomes after the repeated intervention. Exemption from late catchup restenosis required 3-year observation instead of the 1-year mark for conventional treatment. (c) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 50 条
  • [21] Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions
    Horie, Kazunori
    Tanaka, Akiko
    Suzuki, Kenji
    Taguri, Masataka
    Inoue, Naoto
    CVIR ENDOVASCULAR, 2021, 4 (01)
  • [22] Predictors of recurrence after paclitaxel drug-coated balloon use for treating femoropopliteal in-stent restenosis
    Taha, Ashraf Gamal
    Saleh, Mahmoud Ismael
    Ali, Haitham
    Gamal, Walid M.
    VASCULAR, 2024, 32 (04) : 834 - 841
  • [23] The Ranger drug-coated balloon: advances in drug-coated technology for treatment of femoropopliteal segment arterial disease
    Sharma, Navneet
    Finn, Matthew T.
    Parikh, Sahil A.
    Granada, Juan
    FUTURE CARDIOLOGY, 2023, 19 (03) : 127 - 135
  • [24] Drug-coated Balloon Angioplasty in Femoropopliteal Arteries - Is There a Class Effect?
    Teichgraeber, Ulf Karl-Martin
    Klumb, Christof
    ZENTRALBLATT FUR CHIRURGIE, 2017, 142 (05): : 470 - 480
  • [25] Clinical Outcomes of Atherectomy Plus Drug-coated Balloon Versus Drug-coated Balloon Alone in the Treatment of Femoropopliteal Artery Disease
    Cha, Jung-Joon
    Lee, Jae-Hwan
    Ko, Young-Guk
    Roh, Jae-Hyung
    Yoon, Yong-Hoon
    Lee, Yong-Joon
    Lee, Seung-Jun
    Hong, Sung-Jin
    Ahn, Chul-Min
    Kim, Jung-Sun
    Kim, Byeong-Keuk
    Choi, Donghoon
    Hong, Myeong-Ki
    Jang, Yangsoo
    KOREAN CIRCULATION JOURNAL, 2022, 52 (02) : 123 - 133
  • [26] Relationship Between Neutrophil-Lymphocyte Ratio and Drug-Coated Balloon Restenosis in Patients With Femoropopliteal Arterial Disease
    Pan, Tao
    Tian, Shi-yun
    Liu, Zhen
    Zhang, Tao
    Li, Cheng
    Ji, Dong-hua
    Wang, Feng
    ANGIOLOGY, 2023, 74 (03) : 252 - 258
  • [27] Effect of High-Dose Drug-Coated Balloon Repetition After Drug-Coated Balloon Failure
    Tomoi, Yusuke
    Takahara, Mitsuyoshi
    Soga, Yoshimitsu
    Hirano, Taichi
    Tsunoda, Kazuki
    Katsuki, Tomonori
    Ando, Kenji
    JOURNAL OF ENDOVASCULAR THERAPY, 2023,
  • [28] Vessel Patency and Associated Factors of Drug-Coated Balloon for Femoropopliteal Lesion
    Soga, Yoshimitsu
    Takahara, Mitsuyoshi
    Iida, Osamu
    Tomoi, Yusuke
    Kawasaki, Daizo
    Tanaka, Akiko
    Yamauchi, Yasutaka
    Tobita, Kazuki
    Kozuki, Amane
    Fujihara, Masahiko
    Ando, Kenji
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (01):
  • [29] Drug-coated balloon angioplasty versus balloon angioplasty for treating patients with in-stent restenosis in the femoropopliteal artery A meta-analysis
    Cao, Shaobo
    He, Tao
    Xie, Jinfeng
    Feng, Haijun
    Liu, Kui
    Qu, Bihui
    Wu, Xiaoling
    MEDICINE, 2021, 100 (16) : E25599
  • [30] Midterm Outcome of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty Versus Drug-Coated Balloon Angioplasty Alone for Femoropopliteal Arteriosclerosis Obliterans
    Cai, Zhiwen
    Guo, Lianrui
    Qi, Lixing
    Cui, Shijun
    Tong, Zhu
    Guo, Jianming
    Wang, Zhonggao
    Gu, Yongquan
    ANNALS OF VASCULAR SURGERY, 2020, 64 : 181 - 187